CF
CORT icon

Corrigan Financial’s Corcept Therapeutics CORT Stock Holding History

Corrigan Financial’s Portfolio CORT Stock Details CORT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q1 		– Sell
-15,528
Closed -$113K – 40
2016
Q4 		$113K Hold
15,528
– – 0.11% 38
2016
Q3 		$101K Hold
15,528
– – 0.1% 39
2016
Q2 		$84.8K Hold
15,528
– – 0.09% 36
2016
Q1 		$72.7K Hold
15,528
– – 0.07% 45
2015
Q4 		$77.3K Buy
+15,528
New +$70K 0.08% 35

Other funds holding CORT

Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $69.6B AUM 42.52% 1-Year Est. Return
ISL
Ingalls & Snyder LLC New York $3.66B AUM 57.76% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
CCM
Consonance Capital Management New York $7.28M AUM 43.59% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return

Corrigan Financial's CORT Position: Q1 2017 in Review

Corrigan Financial sold out of Corcept Therapeutics (CORT) in Q1 2017, closing a stake of 15,528 shares — an estimated $113K sold.

Corrigan Financial first reported a position in CORT in Q4 2015 and held it in 5 quarters. The position peaked at $113K in Q4 2016. 135 funds tracked by Wall St. Rank hold CORT as of Q1 2017.

  • Corrigan Financial reported no remaining Corcept Therapeutics position as of Q1 2017 after selling out during the quarter.
  • Corrigan Financial sold 15,528 Corcept Therapeutics shares in Q1 2017, an estimated $113K.
  • Corrigan Financial first reported a position in Corcept Therapeutics in Q4 2015 and held it in 5 quarters.
  • Corrigan Financial's Corcept Therapeutics position peaked at $113K in Q4 2016.
  • 135 funds tracked by Wall St. Rank held Corcept Therapeutics as of Q1 2017.

Based on Corrigan Financial's 13F filing for Q1 2017, filed 31 Aug 2023.